Open AccessPatient not adequately controlled with insulin therapy and hospitalized for congestive heart failure
Author(s) -
Vera Frison,
Alessio Filippi,
Natalino Simioni
Publication year - 2018
Publication title -
aboutopen
Language(s) - English
Resource type - Journals
ISSN - 2465-2628
DOI - 10.19156/abtpn.2018.0052
Subject(s) - medicine , empagliflozin , heart failure , insulin , valsartan , cardiology , diabetes mellitus , type 2 diabetes , furosemide , sacubitril, valsartan , intensive care medicine , endocrinology , blood pressure , ejection fraction
The data provided by cardiovascular safety studies of type 2 sodium-glucose transporter inhibitors have aroused great interest among diabetologists and other specialists. They demonstrated that these drugs reduce significantly, compared to placebo, the risk of major cardiovascular events, all cause and cardiovascular mortality, and hospitalization for heart failure in patients with type 2 diabetes at high cardiovascular risk. We report the case of a cardiovascular diabetic patient not adequately controlled by high-dose multi-injective insulin therapy and hospitalized for congestive heart failure, treated with empagliflozin in association with high doses of loop diuretic (furosemide) and sacubitril/valsartan (Diabetology).